首页 | 本学科首页   官方微博 | 高级检索  
     

EGFR、PTEN在常见恶性脑肿瘤中的表达及意义
引用本文:刘家刚,刘艳辉,蔡敬,刘雪松,宋伟正,黄奕,毛庆. EGFR、PTEN在常见恶性脑肿瘤中的表达及意义[J]. 四川大学学报(医学版), 2006, 37(6): 868-871
作者姓名:刘家刚  刘艳辉  蔡敬  刘雪松  宋伟正  黄奕  毛庆
作者单位:四川大学华西医院,神经外科,成都,610041;四川大学华西医院,神经外科,成都,610041;四川大学华西医院,神经外科,成都,610041;四川大学华西医院,神经外科,成都,610041;四川大学华西医院,神经外科,成都,610041;四川大学华西医院,神经外科,成都,610041;四川大学华西医院,神经外科,成都,610041
摘    要:目的探讨表皮生长因子受体(EGFR)和抑癌基因——人10号染色体上缺失的磷酸酶和张力蛋白类似物(PTEN)在常见恶性脑肿瘤中的表达及与脑肿瘤预后的关系。方法应用免疫组织化学SP法结合激光共聚焦免疫荧光显像法对多形性胶质母细胞瘤、髓母细胞瘤、间变性少突胶质细胞瘤和间变性室管膜瘤四种脑肿瘤,共计100例标本的EGFR和PTEN表达进行检测与分析。结果EGFR的阳性率在多形性胶质母细胞瘤、髓母细胞瘤、间变性少突胶质细胞瘤和间变性室管膜瘤中分别是76%(19/25),36%(9/25),28%(7/25)和24%(6/25)。PTEN的阴性率在上述四种肿瘤中为40%(10/25),8%(2/25),8%(2/25),4%(1/25)。PTEN阴性的多形性胶质母细胞瘤患者平均生存时间为7个月,PTEN阳性的患者平均生存时间为18个月。两组患者生存时间差异有统计学意义(P〈0.05)。结论EGFR的过表达和PTEN的缺失在多形性胶质母细胞瘤中常见,并和预后关系密切。但是,在髓母细胞瘤、间变性少突胶质细胞瘤和间变性室管膜瘤中EGFR的过表达和PTEN的缺失不常见。因此针对EGFR和PTEN的靶向治疗在多形性胶质母细胞瘤中有意义,而在其他三种肿瘤中不实用。

关 键 词:表皮生长因子受体  人10号染色体上缺失的磷酸酶和张力蛋白类似物  恶性脑肿瘤
收稿时间:2005-12-30
修稿时间:2006-03-29

Expression of Epidermal Growth Factor Receptor and PTEN in Malignancy Brain Tumors
LIU Jia-gang,LIU Yan-hui,CAI Jing,LIU Xue-song,SONG Wei-zheng,HUANG Yi,MAO Qing. Expression of Epidermal Growth Factor Receptor and PTEN in Malignancy Brain Tumors[J]. Journal of Sichuan University. Medical science edition, 2006, 37(6): 868-871
Authors:LIU Jia-gang  LIU Yan-hui  CAI Jing  LIU Xue-song  SONG Wei-zheng  HUANG Yi  MAO Qing
Affiliation:Department of Nearosurgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Abstract:Objective To detect and analysis epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog deleted on chromosome ten (PTEN) in different malignancy brain tumors, and to evaluate their prognostic significance. Methods Using immunohistochemistry to detect the expression of EGFR and PTEN and adopting confocal technology to verify their location in the specimens of 25 respectively glioblastoma multiformes, medulloblastomas, anaplastic oligodendrogliomas, and anaplastic ependymomas. Results 76% of glioblastoma multiformes had amplification of EGFR, and 40% of which lost PTEN. Patients with these phenomena had a poor survival prognosis, 7 months VS 18 months. However amplification of EGFR and deletion of PTEN were relatively low in other malignancy brain tumors. They were 36% and 8% in medulloblastomas, and 28% and 8% in anaplastic oligodendrogliomas, and 24% and 4% in anaplastic ependymomas. Conclusions PTEN mutation and EGFR amplification are important prognostic factors in patients with glioblastoma multiformes. PTEN mutation and EGFR overexpression are rare in medulloblastoma, anaplastic oligodendroglioma, and anaplastic ependymoma,so the EGFR or PTEN targeted antitumor approaches may be useful in glioblastoma multiformes but the other 3 tumors.
Keywords:EGFR PTEN Malignancy brain tumor
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号